We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Association of G9a Protein and Outcome of Patients With Endometrial Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01271764
Recruitment Status : Completed
First Posted : January 7, 2011
Last Update Posted : September 26, 2012
Sponsor:
Information provided by (Responsible Party):

Study Description
Brief Summary:
Tumor invasion and metastasis are the major causes of cancer-related death. Some studies have found that histone methyltransferases, such as EZH2, specifically affect metastasis in breast, gastric and prostate cancer. The functional roles of other members of the HMT family such as G9a in cancer remain obscure. Therefore, the investigators will investigate whether G9a have a role in recurrence/metastasis of endometrial cancer.

Condition or disease Intervention/treatment
Outcome of Endometrial Cancer Other: no drug

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 97 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Study Start Date : January 2011
Primary Completion Date : July 2012
Study Completion Date : September 2012
Arms and Interventions

Arm Intervention/treatment
No Intervention: endometrial cancer Other: no drug
The role of G9a protein in patients with endometrial cancer


Outcome Measures

Primary Outcome Measures :
  1. The role of G9a protein in endometrial cancer [ Time Frame: overall survial, disease-free survival ]
    We will correlate the G9a protein and outcome of endometrial cancer


Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • all cases with endometrial cancer underwent staging operation

Exclusion Criteria:

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01271764


Locations
Taiwan
Department of Obstetrics and Gynecology, Far-Eastern Memorial Hospital
Banqiao, New Taipei, Taiwan, 22050
Sponsors and Collaborators
Far Eastern Memorial Hospital
More Information

Responsible Party: Sheng-Mou Hsiao, Chief, Department of Obstetrics & Gynecology, Far Eastern Memorial Hospital
ClinicalTrials.gov Identifier: NCT01271764     History of Changes
Other Study ID Numbers: 099095-E
First Posted: January 7, 2011    Key Record Dates
Last Update Posted: September 26, 2012
Last Verified: September 2012

Additional relevant MeSH terms:
Endometrial Neoplasms
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Uterine Diseases
Genital Diseases, Female